Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:9/10/2007

vals have been sought for treating advanced stage, recurrent or metastatic disease. It takes a very long time to get to the Phase III trial stage for a first line indication and only drugs that have a very good safety profile have a chance to qualify. Fortunately that long and difficult road is now behind us!

When a drug is approved as, or as an integral part of, first line standard of care for a given disease, every patient diagnosed with that disease is supposed to receive the drug and reimbursement should be customary. Approval as part of first line standard of care for advanced primary head and neck cancer should translate into billions of dollars in sales and assure blockbuster status to Multikine. Since CEL-SCI still owns all of the major marketing rights to Multikine, our shareholders, in addition to the patients, would be the greatest beneficiaries of such a phenomenal success.

Attempts to use the power of the immune system to fight cancer date from the early 20th century observation of a New York surgeon, Dr. William B. Coley, that some sarcoma patients who suffered severe bacterial infections underwent spontaneous regression of their tumors. Due to limited knowledge of the immune system, progress in using immunotherapy was very slow. Efforts to treat cancer using immunotherapy were limited and empiric.

Advances in science, immunology and technology in the late 1970's have made possible a more complete understanding of the molecular and cellular components and functions of the immune system. Since then, there has been an explosion of interest in immunotherapy and extensive efforts have been made to develop immunotherapeutic drugs and vaccines to treat cancer. Despite these extensive efforts, no drug or vaccine has been developed that by itself is totally effective in maximally harnessing the power of the immune response to fight cancer. Nevertheless, many opinion leaders still believe that immunotherapy is the next great hope for an effect
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
3. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
4. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
5. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
6. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
7. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
8. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
9. Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
10. State of Diabetes in Pittsburgh: Pittsburgh Business Group on Health Releases Report
11. Bipolar Disorder in Children Difficult to Diagnose, Reports the Harvard Mental Health Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and AUSTIN, Texas , ... PureMHC LLC today announced they have entered into ... antibody-based immunotherapies designed to target cancers. ... peptides displayed on the surfaces of tumor cells ... targets (PTTs), derived from proteins that play a ...
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, ... that results from the  IAP310 study have been ... (RAPM), a peer-reviewed journal with broad, multidisciplinary ... trial evaluating the safety and efficacy of Zalviso, ... system (SSTS), for the treatment of post-operative pain ...
(Date:10/22/2014)... 22, 2014  Regulus Therapeutics Inc. (NASDAQ: ... leading the discovery and development of innovative ... has demonstrated human proof-of-concept with a microRNA ... RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ... virus infection ("HCV").  Interim results from the ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... 2010 Reportlinker.com announces that a new market ... TOP 10 DRUG DISCOVERY TECHNOLOGIES – ... http://www.reportlinker.com/p0330501/TOP-10-DRUG-DISCOVERY-TECHNOLOGIES-–-STRATEGIC-ANALYSIS-AND-GLOBAL-FORECASTS.html Top 10 drug ... (2010 to 2015) The top 10 ...
... 18, 2010 Reportlinker.com announces that a ... its catalogue: Global Blood ... http://www.reportlinker.com/p092555/Global-Blood-Pressure-Monitoring--Measurement-Instruments-Industry.html ... for Blood Pressure Measurement Instruments in US$ ...
Cached Medicine Technology:Reportlinker Adds TOP 10 DRUG DISCOVERY TECHNOLOGIES - STRATEGIC ANALYSIS AND GLOBAL FORECASTS 2Reportlinker Adds TOP 10 DRUG DISCOVERY TECHNOLOGIES - STRATEGIC ANALYSIS AND GLOBAL FORECASTS 3Reportlinker Adds TOP 10 DRUG DISCOVERY TECHNOLOGIES - STRATEGIC ANALYSIS AND GLOBAL FORECASTS 4Reportlinker Adds TOP 10 DRUG DISCOVERY TECHNOLOGIES - STRATEGIC ANALYSIS AND GLOBAL FORECASTS 5Reportlinker Adds TOP 10 DRUG DISCOVERY TECHNOLOGIES - STRATEGIC ANALYSIS AND GLOBAL FORECASTS 6Reportlinker Adds TOP 10 DRUG DISCOVERY TECHNOLOGIES - STRATEGIC ANALYSIS AND GLOBAL FORECASTS 7Reportlinker Adds TOP 10 DRUG DISCOVERY TECHNOLOGIES - STRATEGIC ANALYSIS AND GLOBAL FORECASTS 8Reportlinker Adds TOP 10 DRUG DISCOVERY TECHNOLOGIES - STRATEGIC ANALYSIS AND GLOBAL FORECASTS 9Reportlinker Adds TOP 10 DRUG DISCOVERY TECHNOLOGIES - STRATEGIC ANALYSIS AND GLOBAL FORECASTS 10Reportlinker Adds TOP 10 DRUG DISCOVERY TECHNOLOGIES - STRATEGIC ANALYSIS AND GLOBAL FORECASTS 11Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 2Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 3Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 4Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 5Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 6Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 7Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 8Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 9Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 10Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 11Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 12Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 13Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 14Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 15Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 16Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 17Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 18Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 19Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 20Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 21Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 22Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 23Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 24Reportlinker Adds Global Blood Pressure Monitoring & Measurement Instruments Industry 25
(Date:10/22/2014)... Akeso Biomedical, Inc. , a ... of bacterial infections, microbial biofilms, and chronic wounds, announced ... of directors. , Dr. Sinskey is ... Massachusetts Institute of Technology, or MIT. He has been ... Sinskey also holds positions as Co-Director of the Malaysia-MIT ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... men may lead to increased blood pressure, according to a ... rise in blood pressure for young adult women or for ... women drank lightly or moderately, their risk of high blood ... finding parallels studies in older adult men and women," said ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 ... while working for NBC News in Liberia has cleared ... unit at Nebraska Medical Center in Omaha, where he had been ... A blood test confirmed by the U.S. Centers for Disease Control ... Providence, R.I., NBC News reported Tuesday night. "Recovering ...
(Date:10/20/2014)... MA (PRWEB) October 20, 2014 ... sponsoring a booth at the American Foundation for Suicide ... 25th. The AFSP is a not-for-profit organization that hosts ... Net proceeds from these events are used to help ... but education and personal relationships as well. , ...
(Date:10/20/2014)... hc1.com today announced the launch ... that enables healthcare organizations of all sizes to ... relationship management (“CRM”) solution. , Designed from the ... the healthcare industry, the hc1 Healthcare Relationship Cloud™ ... by combining healthcare CRM, HIPAA-compliant collaboration, and real-time ...
Breaking Medicine News(10 mins):Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2
... ... fun, easy, and convenient. Your location or ours, we can fulfill your CPR and First Aid ... (PRWEB) February 19, 2010 -- ... more traditional methods. The hands only CPR movement has been gaining momentum in the last few ...
... , ... ... ... ...
... , ... ... ... ...
... A UCSF team, ... for embryonic stem cell research be modified to better protect the rights of individuals donating ... ... bioethicist Bernard Lo, MD, recommends that the National Institutes of Health ethics guidelines for embryonic ...
... , , WASHINGTON , Feb. 18 ... The Children,s House Inc. of Broadview Heights, Ohio , a ... asthma as required by the Americans with Disabilities Act (ADA). ... to children with asthma whose families seek child care and wish ...
... , Shinseki Asks VA Employees To ... Feb. 18 Secretary of Veterans Affairs Eric ... an employee-based Health Information Technology (HIT) competition to spur VA,s ... and forward-looking.   , "This competition is rooted in the ...
Cached Medicine News:Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 2Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 3Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 4Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 5Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 6Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 7Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 8Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 9Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 10Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 11Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 12Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 13Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 14Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 15Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 16Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 17Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 18Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 19Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 20Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 21Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 22Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 23Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 24Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 25Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 26Health News:'The Dance' Fundraising Event on February 25th Will Feature Belladiva Show Band; Silent Auction Items Include a Two-Week Condo Stay in New Zealand 2Health News:'The Dance' Fundraising Event on February 25th Will Feature Belladiva Show Band; Silent Auction Items Include a Two-Week Condo Stay in New Zealand 3Health News:'The Dance' Fundraising Event on February 25th Will Feature Belladiva Show Band; Silent Auction Items Include a Two-Week Condo Stay in New Zealand 4Health News:'The Dance' Fundraising Event on February 25th Will Feature Belladiva Show Band; Silent Auction Items Include a Two-Week Condo Stay in New Zealand 5Health News:'The Dance' Fundraising Event on February 25th Will Feature Belladiva Show Band; Silent Auction Items Include a Two-Week Condo Stay in New Zealand 6Health News:NIH Stem Cell Guidelines Should Be Modified, UCSF Team Reports 2Health News:NIH Stem Cell Guidelines Should Be Modified, UCSF Team Reports 3Health News:NIH Stem Cell Guidelines Should Be Modified, UCSF Team Reports 4Health News:Justice Department Settles With Ohio Child Care Center to End Discrimination Against Children With Asthma 2Health News:'Innovation Initiative' Underway for Health Records Improvements 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: